About
Pims-e develops a dry powder inhalation technology that serves as a fast-acting alternative to epinephrine auto-injectors for treating life-threatening allergic reactions, eliminating the need for injections or refrigeration.
Explore Pims-e's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.